<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Immunizations in solid organ transplant candidates and recipients</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Immunizations in solid organ transplant candidates and recipients</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Immunizations in solid organ transplant candidates and recipients</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Camille N Kotton, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia L Hibberd, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 26, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prevention of infection is of paramount importance to the increasing population of solid organ transplant recipients. Infection in these patients results in substantial morbidity and mortality, and antimicrobial therapy is often less effective than in the immunocompetent host. Although immunization appears to be an obvious way to prevent infection, immunocompromised patients are less likely to mount protective immune responses following vaccination. While concern had been raised that vaccination might trigger rejection, there does not appear to be a causal association between vaccination and organ rejection and transplant guidelines and programs support vaccination. Immunization with live virus vaccines is generally avoided in solid organ transplant recipients as it may result in adverse events from proliferation of attenuated vaccine strains.</p><p>Our approach to immunizing patients who are awaiting or have undergone solid organ transplantation will be reviewed here. Issues related to immunizations in patients who have had hematopoietic cell transplants, who have undergone chemotherapy for treatment of hematologic malignancies or solid tumors, who have human immunodeficiency virus (HIV) infection, patients with impaired splenic function, and in healthy adults are discussed separately. (See  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients"</a> and  <a class="medical medical_review" href="/d/html/3899.html" rel="external">"Immunizations in adults with cancer"</a> and  <a class="medical medical_review" href="/d/html/3706.html" rel="external">"Immunizations in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">IMMUNOGENICITY</span><span class="headingEndMark"> — </span>The risk of acquiring infection and the inability to prevent infection by immunization are directly related to the patient's "net state of immunosuppression." The greater the degree of immunosuppression, the less likely the patient is to respond to immunization. Factors contributing to immunosuppression in solid organ transplant recipients include the underlying disease (eg, renal or hepatic insufficiency), the post-transplant immunosuppressive regimen, the presence of allograft rejection, advanced age, and other comorbidities (eg, diabetes mellitus, asplenia).</p><p>Although vaccination is likely to provide benefit to the immunocompromised patient, an adequate vaccine response cannot be assumed [<a href="#rid1">1-3</a>]. Protection of the immunocompromised patient may require the use of vaccines and/or passive immunization (ie, intravenous immunoglobulin) as well as adjunctive measures, such as antiviral drug prophylaxis after influenza exposure.</p><p>While concern has been raised that vaccination might trigger rejection, numerous trials have shown no causal association between vaccination and organ rejection [<a href="#rid4">4,5</a>].</p><p class="headingAnchor" id="H3"><span class="h1">TIMING OF IMMUNIZATIONS</span></p><p class="headingAnchor" id="H113799911"><span class="h2">Pretransplant</span><span class="headingEndMark"> — </span>Prior to transplantation, we review each patient's vaccination and exposure history in detail along with their serology results and administer any indicated vaccinations  (<a class="graphic graphic_table graphicRef122440" href="/d/graphic/122440.html" rel="external">table 1</a>) [<a href="#rid1">1,6</a>] (see  <a class="medical medical_review" href="/d/html/1398.html" rel="external">"Evaluation for infection before solid organ transplantation"</a>). A programmatic approach to pretransplant vaccination has been shown to be beneficial and conveys better protection against infection [<a href="#rid7">7</a>]. Many transplant programs have initiated routine pretransplant vaccination programs. In general, updating COVID-19, pneumococcal, influenza, and tetanus immunizations, along with serology-based vaccine recommendations against measles, mumps, varicella/herpes zoster, hepatitis B virus, and hepatitis A virus, are key interventions.</p><p>Standard vaccines for children are summarized in the following figures  (<a class="graphic graphic_figure graphicRef82617" href="/d/graphic/82617.html" rel="external">figure 1B</a> and <a class="graphic graphic_figure graphicRef58209" href="/d/graphic/58209.html" rel="external">figure 1A</a>). Standard vaccines for adults with medical conditions are summarized in the following figure  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1C</a>). (See  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/1963.html" rel="external">"Immunizations in patients with end-stage kidney disease"</a> and  <a class="medical medical_review" href="/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease"</a> and  <a class="medical medical_review" href="/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Routine schedule'</a>.)</p><p>The pretransplant period is an important window of opportunity to optimize protection against vaccine-preventable illness. Although vaccine responses may be diminished in some patients during this period, vaccine responses are generally even more attenuated post-transplantation when the patient is immunosuppressed [<a href="#rid1">1-3</a>]. Since vaccine immunogenicity is often diminished in the setting of organ failure, transplant candidates should be immunized as early in the course of their disease as possible [<a href="#rid8">8,9</a>]. In addition, live virus vaccines (eg, measles, mumps, rubella, varicella, and the intranasal influenza vaccine) are usually avoided post-transplantation. The Infectious Diseases Society of America recommends waiting a minimum of four weeks between live virus vaccine administration and subsequent transplantation [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H113799917"><span class="h2">Post-transplant</span><span class="headingEndMark"> — </span>Optimal timing is important in maximizing the response to immunization following solid organ transplantation. It is common to wait at least 3 and often up to 12 months after transplantation before giving vaccines, once maintenance immunosuppression levels have been attained [<a href="#rid6">6,8</a>]. An exception is that during influenza outbreaks, it is reasonable to give the <a class="drug drug_general" data-topicid="9055" href="/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a> as early as one month following transplantation [<a href="#rid6">6</a>]; most programs give influenza vaccine starting three months after transplant. Although there had been some concern about vaccine safety after transplant, multiple studies have shown that inactivated vaccines are safe and not associated with organ rejection following transplantation [<a href="#rid10">10-16</a>]. Live vaccines are generally contraindicated post-transplantation when patients are immunosuppressed.</p><p>The timing of vaccination may need to be modified when immunomodulatory treatment is given for rejection (eg, anti-CD20 antibodies, antithymocyte globulin). While specific timing will vary based on individual circumstance, we generally try to vaccinate when the effect of any immunosuppressive agents is at its nadir to maximize the likelihood of developing a protective immune response. We often avoid vaccination, other than seasonal influenza, for six months following treatment for rejection.</p><p class="headingAnchor" id="H5"><span class="h1">INACTIVATED VACCINES</span></p><p class="headingAnchor" id="H716713214"><span class="h2">Influenza</span><span class="headingEndMark"> — </span>Annual administration of an inactivated seasonal influenza vaccine is indicated for all transplant candidates and recipients, including during the first year following transplantation [<a href="#rid8">8</a>]. When vaccinating, we generally prefer the high-dose influenza vaccine for adults because it increases the likelihood of developing a more robust immune response [<a href="#rid17">17-19</a>]; however, using the standard-dose vaccine is also reasonable.</p><p>We typically resume vaccinations for influenza approximately three to six months after transplantation once maintenance immunosuppression levels have been attained. In the United States, the Centers for Medicare and Medicaid Services have recommended that all patients, including transplant recipients, be immunized prior to discharge from the hospital. This may result in some patients being immunized very early following transplantation causing suboptimal immune responses to the vaccine. Revaccination of such patients three to six months following transplantation can be considered if there is still influenza activity. (See <a class="local">'Timing of immunizations'</a> above.)</p><p>Influenza is a common infection in solid organ transplant recipients and is associated with high morbidity and mortality [<a href="#rid20">20</a>]. In addition to the usual complications of influenza (eg, pneumonia), influenza infection may also be associated with rejection in solid organ transplant recipients [<a href="#rid21">21</a>]. Although the immune response to influenza vaccines is less robust and more heterogenous in solid organ transplant recipients when compared with healthy individuals, vaccination is still effective in preventing and reducing the severity of influenza infection [<a href="#rid10">10,15,22-28</a>]. As an example, in an observational study of lung transplant recipients who received one or two doses of an adjuvanted monovalent 2009 to 2010 pandemic H1N1 influenza vaccine versus no vaccine, documented influenza infection occurred in 2 of 148 vaccinated patients (1.3 percent) compared with 5 of 20 unvaccinated patients (25 percent) [<a href="#rid29">29</a>]. In a multicenter prospective observational study of 616 transplant recipients with confirmed influenza, prior vaccination during that season was associated with reduced rates of pneumonia (odds ratio [OR] 0.34, 95% CI 0.21-0.55) and admissions to the intensive care unit (OR 0.49, 95% CI 0.26-0.90) [<a href="#rid27">27</a>]. The degree of protection from vaccination likely varies based on circulating influenza strains, the intensity of the post-transplant immunosuppressive regimen, and time since transplantation [<a href="#rid3">3,15,30,31</a>].</p><p>Several strategies have been employed to augment vaccine immunogenicity in solid organ transplant recipients [<a href="#rid32">32</a>]. Among them, use of a high-dose <a class="drug drug_general" data-topicid="9055" href="/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a> appears most efficacious. As an example, in one randomized trial evaluating 172 solid organ transplant recipients, seroconversion rates and postimmunization antibody titers were significantly higher among solid organ transplant recipients who were vaccinated with a high-dose influenza vaccine when compared with a standard-dose vaccine [<a href="#rid17">17</a>]. While rejection rates did not differ between groups, the study was not powered for this outcome. Booster dosing may also improve immunogenicity, though results among studies have varied [<a href="#rid25">25,32,33</a>]. Intradermal vaccination and adjuvanted standard-dose vaccination have not been shown to improve immunogenicity.</p><p>Use of inactivated influenza vaccines is considered safe following solid organ transplantation. While there is a theoretical concern that vaccination may trigger organ rejection [<a href="#rid34">34,35</a>], this association has not been reported in clinical trials [<a href="#rid11">11,32,36-38</a>]. By contrast, in a retrospective cohort study of 51,730 adult renal transplant recipients receiving Medicare, influenza vaccination during the first year after transplantation was associated with lower risk of subsequent allograft loss and death [<a href="#rid16">16</a>]. Like all live virus vaccines, the <a class="drug drug_general" data-topicid="9056" href="/d/drug information/9056.html" rel="external">live attenuated influenza vaccine</a> is contraindicated in solid organ transplant recipients. (See <a class="local">'Live virus vaccines'</a> below.)</p><p>Although vaccination against seasonal influenza appears effective and safe, protection is incomplete. Solid organ transplant recipients exposed to influenza or those who have inadvertently received a live formulation of the influenza vaccine are candidates for antiviral prophylaxis (see  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"</a>). Transplant recipients who develop influenza are candidates for antiviral treatment, regardless of vaccine status. (See  <a class="medical medical_review" href="/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p class="headingAnchor" id="H2380740763"><span class="h2">Pneumococcus</span><span class="headingEndMark"> — </span>We agree with the United States Advisory Committee on Immunization Practices that all solid organ transplant candidates and recipients should be vaccinated against <em>Streptococcus pneumoniae </em>[<a href="#rid39">39</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach in adults</strong> – Adult solid organ transplant candidates and recipients should receive either of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="drug drug_general" data-topicid="131831" href="/d/drug information/131831.html" rel="external">20-valent pneumococcal conjugate vaccine</a> (PCV20) alone <strong>or</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <a class="drug drug_general" data-topicid="132100" href="/d/drug information/132100.html" rel="external">15-valent pneumococcal conjugate vaccine</a> (PCV15) followed by the 23-valent polysaccharide pneumococcal vaccine (<a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a>) ≥8 weeks later [<a href="#rid39">39</a>]. </p><p></p><p class="bulletIndent1">Vaccine selection is based on availability and ease of dosing. </p><p></p><p class="bulletIndent1">For patients who have already received either the <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a> or an older formulation of the pneumococcal conjugate vaccine (eg, <a class="drug drug_general" data-topicid="9906" href="/d/drug information/9906.html" rel="external">13-valent pneumococcal conjugate vaccine</a> [PCV13], <a class="drug drug_general" data-topicid="17136" href="/d/drug information/17136.html" rel="external">10-valent pneumococcal conjugate vaccine</a> [PCV10]) previously, the dosing schedule varies  (<a class="graphic graphic_table graphicRef143140" href="/d/graphic/143140.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef143139" href="/d/graphic/143139.html" rel="external">table 3</a>). Some UpToDate contributors have a different approach to vaccine selection; this is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Approach to vaccination'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="132100" href="/d/drug information/132100.html" rel="external">PCV15</a> and <a class="drug drug_general" data-topicid="131831" href="/d/drug information/131831.html" rel="external">PCV20</a> are pneumococcal conjugate vaccines that are protective against additional pneumococcal serotypes compared with <a class="drug drug_general" data-topicid="9906" href="/d/drug information/9906.html" rel="external">PCV13</a>. Pneumococcal conjugate vaccines that contain a different number of serotypes (eg, the <a class="drug drug_general" data-topicid="17136" href="/d/drug information/17136.html" rel="external">PCV10</a>) are used in some countries in Europe and elsewhere; patients should be vaccinated against pneumococcus according to their national guidelines. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Conjugate vaccines'</a>.)</p><p></p><p class="bulletIndent1">Recommendations for revaccination (eg, booster dosing) with <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a> vary among experts and clinical practice guidelines. Revaccination with pneumococcal conjugate vaccines is not necessary. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults", section on 'Revaccination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach in children </strong>– Pediatric solid organ transplant candidates and recipients should also be vaccinated against pneumococcus [<a href="#rid40">40-42</a>]  (<a class="graphic graphic_algorithm graphicRef119302" href="/d/graphic/119302.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef119305" href="/d/graphic/119305.html" rel="external">algorithm 2</a>). This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children", section on 'Immunization of high-risk children and adolescents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety and efficacy </strong>– Several small cohort studies have evaluated the immune response to pneumococcal vaccination in solid organ transplant recipients [<a href="#rid43">43-47</a>]. In most, organ transplant recipients developed measurable serologic responses to vaccination, but responses were lesser than those in immunocompetent patients. As an example, in one study, immunization with <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a> one year after heart transplantation was successful (defined as protective titers of &gt;300 units/mL to eight of nine selected serotypes) in 75 to 100 percent of recipients [<a href="#rid43">43</a>]. However, only 50 percent of the transplant recipients developed protective levels to pneumococcal serotype 3, compared with a 91 percent response rate in healthy individuals. In trials comparing the 7-valent pneumococcal conjugate vaccine (PCV7) with PPSV23 in renal transplant recipients, there was no difference in immunogenicity between the vaccines [<a href="#rid44">44,45</a>]. Antibody response rates to each individual serotype were poor eight weeks following administration of each vaccine (13 to 40 percent with PPSV23, 17 to 50 percent with PCV7) [<a href="#rid44">44</a>]. Among patients who had adequate responses eight weeks following vaccination, responses to each serotype persisted in only 42 to 85 percent of individuals at three years [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="131831" href="/d/drug information/131831.html" rel="external">PCV20</a> alone and <a class="drug drug_general" data-topicid="132100" href="/d/drug information/132100.html" rel="external">PCV15</a> in series with <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a> have both been shown to be immunogenic and safe, although no studies have compared vaccine effectiveness of PCV20 alone or PCV15 combined with PPSV23 to the <a class="drug drug_general" data-topicid="9906" href="/d/drug information/9906.html" rel="external">PCV13</a> combined with PPSV23 in solid organ transplant recipients [<a href="#rid48">48,49</a>]. </p><p></p><p class="headingAnchor" id="H13"><span class="h2">Hepatitis B</span><span class="headingEndMark"> — </span>Hepatitis B virus vaccination is indicated for all anti-hepatitis B surface antigen (anti-HBs)-negative solid organ transplant candidates [<a href="#rid6">6</a>]. There is no clear consensus on whether a specific vaccine formulation is superior; thus, any vaccine can be used. Because many transplant recipients do not mount an adequate antibody response to vaccination, we check an anti-HBs titer at least a month following a full vaccination series [<a href="#rid50">50-53</a>]. If a titer of ≥10 milli-international units/mL is not attained, revaccination is indicated. The complete high-dose vaccine series can be repeated; alternatively, one additional dose can be given and titers rechecked. Another alternative for revaccination is to give the <a class="drug drug_general" data-topicid="115634" href="/d/drug information/115634.html" rel="external">CpG-adjuvanted recombinant hepatitis B vaccine</a> (HEPLISAV-B); however, some experts have theoretic concerns about adjuvants in organ transplant recipients, as they could alter immunotolerance of the transplanted organ when used after transplant. (See  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Patients on dialysis and immunocompromised hosts'</a>.)</p><p>Since a transplant candidate may be offered an organ from a HBsAg-negative, core antibody-positive ("core-positive") donor, or sometimes even an HBsAg-positive donor, the vaccine series should be completed prior to transplantation whenever possible [<a href="#rid54">54</a>]. The response to hepatitis B vaccine administration after transplantation varies greatly, with ranges reported from 17 to 89 percent [<a href="#rid55">55-57</a>]. Unfortunately, titers decline more rapidly than usual, even in those who develop protective levels of antibody [<a href="#rid55">55,58</a>], and booster doses produce suboptimal responses [<a href="#rid55">55</a>]. These results underscore the value of pretransplant immunization, which generally results in a more robust and durable response, ideally done prior to the onset of advanced renal or liver failure. (See  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults", section on 'Postvaccination testing'</a>.)</p><p>The management of patients with chronic hepatitis B infection who undergo liver transplantation and of HBsAg-negative transplant recipients who receive a liver from a hepatitis B core antibody (anti-HBc)-positive donor is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4584.html" rel="external">"Liver transplantation in adults: Preventing hepatitis B virus infection in liver transplant recipients"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Hepatitis A</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">Hepatitis A vaccine</a> is indicated for all adult liver transplant candidates and recipients because of their increased risk of fulminant hepatic failure from hepatitis A virus (HAV) [<a href="#rid59">59</a>]. Hepatitis A vaccination is also indicated for all pediatric solid organ transplant candidates and recipients ≥12 months of age [<a href="#rid6">6,8</a>] and all nonliver solid organ transplant recipients who have additional risk factors for HAV transmission (eg, clotting factor disorder, travel to or residence in regions where hepatitis A virus is endemic) [<a href="#rid8">8</a>]. Monitoring titers is indicated only for individuals with an ongoing risk of exposure, such as planned travel to an endemic area [<a href="#rid6">6</a>].</p><p>Patients should be vaccinated as early as possible after the diagnosis of chronic liver disease because advanced liver failure blunts the immune response to the vaccine [<a href="#rid60">60</a>]. Several observational studies suggest that receipt of a complete vaccine series prior to solid organ transplantation engenders better immunity than when vaccines are given post-transplantation [<a href="#rid61">61-64</a>]. The duration of both natural immunity and vaccine-induced immunity is also reduced post-transplantation [<a href="#rid61">61,65,66</a>]. In one study of liver transplant recipients who acquired natural hepatitis A infection prior to transplantation, 4 of 22 patients (18 percent) and 7 of 24 patients (29 percent) became seronegative one and two years after transplantation, respectively [<a href="#rid65">65</a>]. While a combination <a class="drug drug_general" data-topicid="8953" href="/d/drug information/8953.html" rel="external">hepatitis A-hepatitis B vaccine</a> (Twinrix) may be efficient, some studies have shown that the combination vaccine is less immunogenic compared with monovalent vaccines [<a href="#rid67">67</a>].</p><p>Additional detail on hepatitis A vaccination is provided separately. (See  <a class="medical medical_review" href="/d/html/3900.html" rel="external">"Hepatitis A virus infection: Treatment and prevention", section on 'Vaccination'</a>.)</p><p class="headingAnchor" id="H3472386024"><span class="h2">Human papillomavirus</span><span class="headingEndMark"> — </span>Female solid organ transplant recipients with human papillomavirus (HPV) infection are at 20- to 100-fold increased risk of cervical intraepithelial neoplasia, and both male and female recipients are at risk for other anogenital cancers [<a href="#rid34">34,68,69</a>]. We recommend vaccinating solid organ candidates and recipients who meet the age-based indications for HPV vaccination [<a href="#rid8">8,69</a>]. (See  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination", section on 'Indications and age range'</a>.)</p><p>Vaccination should be given prior to transplantation when possible. If all doses are not given prior to transplantation, the additional doses can be given beginning three to six months following transplantation. There are few data on the immunogenicity of the HPV vaccination in solid organ transplant recipients, but it should be safe to administer following transplantation since it is not a live vaccine. In one study, the quadrivalent HPV virus-like particle vaccine demonstrated poor immunogenicity in solid organ transplant recipients, with responses ranging from 53 to 68 percent against the four types included in the vaccine [<a href="#rid70">70</a>]. Factors associated with reduced immunogenicity included vaccination early after transplant, having a lung transplant, and having higher <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> levels. At 12 months, there were significant declines in antibody titers to all four HPV types, although the number of patients who remained seropositive did not differ significantly. </p><p>There may be a role for HPV vaccine in both male and female transplant recipients outside the age-based indications to prevent anogenital warts, anal cancer, and HPV-associated skin cancers [<a href="#rid69">69</a>]. In a phase III single-arm study of 171 solid organ recipients aged 18 to 55 years who received the 9-valent HPV vaccine, seroconversion ranged from 46 to 72 percent (depending on HPV serotype) and there were no adverse effects [<a href="#rid71">71</a>]. We anticipate that there will be a future recommendation to broaden the indications for use of the HPV vaccine in transplant recipients, pending reporting of results of an ongoing study of the safety and efficacy of HPV in solid organ transplant recipients up to age 35 years. </p><p>Additional detail on HPV vaccination is provided separately. (See  <a class="medical medical_review" href="/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Meningococcus</span><span class="headingEndMark"> — </span>The incidence of meningococcal disease after solid organ transplantation is unknown, and there is no information on the efficacy of meningococcal vaccines in patients with renal or liver failure or in solid organ transplant recipients. We generally vaccinate solid organ transplant recipients against all five serotypes (A, B, C, W, and Y) who have a specific risk factor for invasive meningococcal infection (eg, asplenia, anticipated use of <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>)  (<a class="graphic graphic_table graphicRef130150" href="/d/graphic/130150.html" rel="external">table 4</a>) [<a href="#rid8">8,72</a>]. </p><p>A special transplant-related indication would be for those transplant recipients who are likely to receive or who have been given the terminal complement pathway inhibitor <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>. Guidelines suggest that for patients who will be starting eculizumab, when possible, vaccination should be completed at least two weeks in advance in order to provide adequate time for an immune response [<a href="#rid8">8</a>]. Many clinicians would still give antibiotic prophylaxis even after appropriate vaccination, as not all strains are covered and the immune response may not be as robust as needed. Some transplant programs give it to highly sensitized patients at higher risk of antibody-mediated rejection and who may need eculizumab.</p><p>Details of meningococcal vaccinations are discussed separately. (See  <a class="medical medical_review" href="/d/html/3901.html" rel="external">"Meningococcal vaccination in children and adults", section on 'Indications and schedules in the United States'</a>.)</p><p class="headingAnchor" id="H1761640162"><span class="h2">Haemophilus influenzae</span><span class="headingEndMark"> — </span>Pediatric solid organ transplant recipients should receive the <em>Haemophilus influenzae</em> type b (Hib) conjugate vaccine according to the routine schedule for children  (<a class="graphic graphic_figure graphicRef82617" href="/d/graphic/82617.html" rel="external">figure 1B</a> and <a class="graphic graphic_figure graphicRef58209" href="/d/graphic/58209.html" rel="external">figure 1A</a>). Hib titers should be checked at least four weeks after vaccine administration if serologic testing is available; a titer &gt;0.15 mg/L is considered protective in the general population [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/6022.html" rel="external">"Prevention of <i>Haemophilus influenzae</i> type b infection", section on 'Routine schedule'</a>.)</p><p>Among adults, Hib is generally only recommended for individuals with impaired splenic function and following stem cell transplantation. (See  <a class="medical medical_review" href="/d/html/1412.html" rel="external">"Prevention of infection in patients with impaired splenic function", section on 'Vaccinations'</a> and  <a class="medical medical_review" href="/d/html/3882.html" rel="external">"Immunizations in hematopoietic cell transplant candidates and recipients", section on 'Haemophilus influenzae'</a>.)</p><p class="headingAnchor" id="H1991281863"><span class="h2">Tetanus, diphtheria, and pertussis</span><span class="headingEndMark"> — </span>The tetanus, diphtheria, pertussis (Tdap), the diphtheria, tetanus, pertussis (DTaP), and the tetanus, diphtheria (Td) vaccines should be given per the same indications and schedules as the general population  (<a class="graphic graphic_figure graphicRef58209 graphicRef82617 graphicRef62130" href="/d/graphic/58209.html" rel="external">figure 1A-C</a>).</p><p>Like other inactivated vaccines, these vaccines can be safely given post-transplantation when needed [<a href="#rid34">34,73,74</a>]. Observational data suggest that there is no increased risk of rejection following vaccination. However, the immune response to these vaccines may be blunted [<a href="#rid73">73-76</a>]. The American Society of Transplantation guidelines recommend monitoring tetanus titers in pediatric (but not adult) solid organ transplant candidates and recipients a minimum of four weeks following vaccination [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/2838.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"</a> and  <a class="medical medical_review" href="/d/html/2844.html" rel="external">"Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age", section on 'Schedules'</a> and  <a class="medical medical_review" href="/d/html/3897.html" rel="external">"Tetanus-diphtheria toxoid vaccination in adults"</a>.)</p><p class="headingAnchor" id="H992840160"><span class="h2">COVID-19 vaccine</span><span class="headingEndMark"> — </span>SOT candidates and recipients should be vaccinated against coronavirus disease 2019 (COVID-19). This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Vaccination'</a>.)</p><p class="headingAnchor" id="H501544121"><span class="h2">Respiratory syncytial virus (RSV)</span><span class="headingEndMark"> — </span>Solid organ transplant recipients are at high risk for RSV disease. In accordance with the ACIP, we discuss the benefits and potential risks and use shared clinical decision making to help decide whether the RSV vaccine is the right choice for SOT candidates and recipients who are ≥60 years old  (<a class="graphic graphic_table graphicRef143553" href="/d/graphic/143553.html" rel="external">table 5</a>) [<a href="#rid77">77</a>]. </p><p>Although the vaccine has not been studied in SOT candidates and recipients, given the high burden of disease, we believe the benefits outweigh the potential risks, especially in patients at higher risk, such as lung transplant recipients, those with underlying lung conditions (eg, COPD), and those who have frequent exposure to young children or are in group living situations.</p><p>However, given likely diminished immunogenicity, we defer administering the vaccine to SOT recipients ≥60 years old who: </p><p class="bulletIndent1"><span class="glyph">●</span>received a transplant &lt;1 year ago </p><p></p><p class="bulletIndent1">or </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>are experiencing rejection or have received treatment for rejection in the past three months </p><p></p><p>These patients are severely immunosuppressed and are unlikely to mount an effective response to the vaccine. We revisit discussion of vaccination in such patients once they are no longer severely immunosuppressed. </p><p>Administration, efficacy, and safety of the vaccine is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/142052.html" rel="external">"Respiratory syncytial virus infection in adults"</a>.)</p><p class="headingAnchor" id="H468261419"><span class="h1">ZOSTER VACCINES</span><span class="headingEndMark"> — </span>There are two vaccine formulations available for the prevention of herpes zoster: the recombinant (nonlive) glycoprotein E vaccine (<a class="drug drug_general" data-topicid="115351" href="/d/drug information/115351.html" rel="external">recombinant zoster vaccine</a> [RZV]; sold as Shingrix) and the live attenuated vaccine (<a class="drug drug_general" data-topicid="10340" href="/d/drug information/10340.html" rel="external">zoster vaccine live</a> [ZVL] that is no longer available in the United States) [<a href="#rid78">78</a>]. </p><p>We agree with the recommendations from the United States Advisory Committee on Immunization Practices to vaccinate immunocompromised (or soon to be immunocompromised) individuals ≥19 years old, such as solid organ transplant candidates and recipients, against herpes zoster with the <a class="drug drug_general" data-topicid="115351" href="/d/drug information/115351.html" rel="external">recombinant zoster vaccine</a> (RZV) [<a href="#rid79">79</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>RZV as preferred option</strong> − RZV is administered in two doses spaced two to six months apart. However, in patients who are or will be immunosuppressed and would benefit from receiving the full vaccination series earlier, the second dose can be given as early as four weeks after the first dose. Like other vaccines, the vaccine should ideally be given before transplantation to help ensure maximal immune response. Vaccination with the RZV series should be completed at least two weeks prior to transplantation. </p><p></p><p class="bulletIndent1">RZV appears to be effective and safe in solid organ transplant recipients. In a randomized trial in 264 adult renal transplant recipients, vaccination boosted cellular and humoral immune responses when compared with placebo, with higher responses seen in younger adults (&lt;50 years old) [<a href="#rid80">80</a>]. There was no difference in graft rejection rates between the RZV and placebo groups. Small, observational studies have also demonstrated efficacy and safety of RZV in other solid organ transplant recipients [<a href="#rid81">81</a>]. </p><p></p><p class="bulletIndent1">RZV appears to be more effective than ZVL in the general health population and is not associated with a risk of disseminated disease. In a systematic network meta-analysis of randomized trials of healthy adults 60 years or older, ZVL was approximately half as effective in preventing zoster infection compared with RZV [<a href="#rid82">82</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ZVL as less preferred alternative</strong> − In settings where RZV is not available, ZVL is an alternative option for vaccination against herpes zoster. ZVL is administered as a single dose and should be given at least four weeks prior to transplantation. ZVL is <strong>contraindicated</strong> in solid organ transplant recipients post-transplantation because it is a live virus vaccine [<a href="#rid8">8,83</a>]. ZVL is not as effective as RZV; thus in patients who receive ZVL, consider revaccinating with RZV once it becomes available.</p><p></p><p>Additional detail on the vaccination of the prevention of herpes zoster is provided separately. (See  <a class="medical medical_review" href="/d/html/8343.html" rel="external">"Vaccination for the prevention of shingles (herpes zoster)"</a>.)</p><p class="headingAnchor" id="H17"><span class="h1">LIVE VIRUS VACCINES</span><span class="headingEndMark"> — </span>The Infectious Diseases Society of America (IDSA) recommends waiting a minimum of four weeks between live virus vaccine administration and solid organ transplantation [<a href="#rid6">6</a>]. Live organism vaccines are generally avoided following solid organ transplantation (or in those candidates who are immunosuppressed before transplant) given the potential for active infection. A list of live vaccines is provided in the following table  (<a class="graphic graphic_table graphicRef112956" href="/d/graphic/112956.html" rel="external">table 6</a>).</p><p>The following caveats should be noted regarding the administration of live virus vaccines prior to transplantation [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The measles, mumps, and rubella (MMR) vaccine and the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> can be administered on the same day, but if they are not given on the same day, the second live vaccine should be administered at least 28 days after the first.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Live vaccines can interfere with the response to the <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST). A TST can be placed the same day as a live vaccine is given, but if it is not done on the same day, it should be delayed for four to six weeks. An alternative to the TST is the interferon-gamma release assay for tuberculosis, which may have higher sensitivity in patients with end-stage organ disease [<a href="#rid84">84,85</a>]. (See  <a class="medical medical_review" href="/d/html/1407.html" rel="external">"Tuberculosis in solid organ transplant candidates and recipients", section on 'Screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>) and antibodies transferred with blood products can bind vaccine and interfere with the immune response to live virus vaccines. Thus, administering MMR vaccine as well as the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> should be delayed after receipt of IVIG and other blood products  (<a class="graphic graphic_table graphicRef72640" href="/d/graphic/72640.html" rel="external">table 7</a>). Delay is not needed before the administration of inactivated vaccines (eg, <a class="drug drug_general" data-topicid="115351" href="/d/drug information/115351.html" rel="external">recombinant zoster vaccine</a>). (See  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy", section on 'Vaccination of patients receiving IVIG'</a>.)</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Measles, mumps, and rubella</span><span class="headingEndMark"> — </span>Measles, mumps, and rubella infections are rare after solid organ transplantation, but the potential severity of these diseases is well recognized for nonimmunized individuals. All children should ideally receive a two-dose series of the MMR vaccine, with at least four weeks between doses [<a href="#rid8">8</a>]. In one study of children who were on dialysis when they received the MMR vaccine, 70, 50, and 80 percent developed protective titers against measles, mumps, and rubella, respectively, but only 30 percent were protected against all three infections [<a href="#rid86">86</a>]. Every effort should be made to immunize such transplant candidates at least one month prior to transplantation [<a href="#rid6">6,42</a>]. We suggest checking antibody titers after immunization prior to transplantation because of the variability in the vaccine response.</p><p>In order to immunize pediatric solid organ transplant candidates younger than one year of age prior to transplantation, the American Society of Transplantation (AST) and the IDSA state that the MMR vaccine can be given as early as six months of age in infants not receiving immunosuppression, although the vaccine is most effective after one year of age when maternal antibodies have waned [<a href="#rid6">6,8</a>]. Data suggest excellent immunogenicity in those infants with chronic renal failure and/or receiving peritoneal dialysis [<a href="#rid87">87</a>]. If transplantation has not occurred by one year of age, a second dose should be given, provided that a minimum of four weeks has elapsed since the previous dose. At least four weeks should elapse between live virus vaccine administration and transplantation. Several caveats are reviewed above. (See <a class="local">'Live virus vaccines'</a> above.)</p><p>Based upon the severe complications related to measles infection in transplant recipients and the experience of administering MMR in children infected with HIV [<a href="#rid88">88</a>], some transplant centers have started to use MMR after solid organ transplantation for children or others who have not completed the recommended series of MMR [<a href="#rid89">89</a>], primarily in those on low-dose immunosuppression [<a href="#rid90">90</a>]. However, this practice is not widespread and safety data are limited [<a href="#rid91">91</a>]. In one study, 7 of 17 seronegative pediatric liver transplant recipients developed protective titers against measles after immunization, and none developed clinical measles [<a href="#rid92">92</a>]. In another study, 44 pediatric liver transplant recipients who were ≥1 year post-transplantation on low-dose immunosuppression with lymphocyte counts ≥0.75 G/L were given MMR vaccine without any serious adverse events [<a href="#rid90">90</a>]. Vaccination was given a median of 6.3 years post-transplantation, and seroprotection was achieved in most patients following 1 to 3 doses of MMR. However, these limited data are inadequate to support a recommendation for post-transplant immunization with MMR in nonimmune individuals. Guidelines from the AST Infectious Diseases Community of Practice state "MMR and varicella vaccination are generally contraindicated post-transplant but may be administered in carefully selected patients with appropriate education and close follow-up" [<a href="#rid8">8</a>].</p><p>Nonimmune adult solid organ transplant candidates should receive MMR vaccination prior to transplantation. The optimal approach is not known. Some experts give a total of two MMR doses prior to transplantation while others give a single dose and test for a protective serologic response ≥4 weeks later. If seroconversion has not occurred, a second dose can be given prior to transplantation, if time permits. A key caveat is that the MMR is a live vaccine, which must be given at least four weeks prior to transplantation.</p><p>Nonimmune solid organ transplant recipients and those who are severely immunocompromised who have been exposed to measles should receive postexposure prophylaxis with intravenous <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>. (See  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults", section on 'Post-exposure prophylaxis'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Varicella</span><span class="headingEndMark"> — </span>Given the risk of severe varicella infection (chickenpox) in nonimmune solid organ transplant recipients, we suggest immunization with the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> at least four weeks prior to transplantation [<a href="#rid6">6</a>]. Because patients with end-stage organ disease have reduced seroconversion rates of approximately 60 percent to varicella vaccination [<a href="#rid93">93-96</a>], it is particularly important for such patients to receive two doses of the varicella vaccine, if feasible, with a minimum interval of four weeks between doses for individuals aged ≥13 years and a minimum interval of three months for individuals aged 1 to 12 years [<a href="#rid6">6,83</a>]. (See  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Schedules in the United States'</a>.)</p><p>Maternal antibodies interfere with the response to varicella vaccination, and the vaccine is most effective after one year of age when maternal antibodies have waned [<a href="#rid8">8</a>]. Infants awaiting transplantation may receive the vaccine as early as six months of age [<a href="#rid6">6</a>]. Varicella antibodies should be checked four weeks after the second dose of vaccine has been given [<a href="#rid8">8</a>]. If seroconversion does not occur, an additional dose can be given if time permits. Those who do not seroconvert are candidates for postexposure prophylaxis, should an exposure occur following transplantation. (See <a class="local">'Postexposure prophylaxis'</a> below.)</p><p>A potential concern for patients high on the waiting list is the possibility that transplantation could occur shortly after vaccination, subjecting a recently vaccinated patient to high-dose immunosuppression and the risk of proliferation of the attenuated strain. As noted above, transplant candidates should be vaccinated at least four weeks prior to transplant [<a href="#rid6">6</a>]. If transplantation is urgently indicated in a patient who has received the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> within the previous month, peri- and post-transplant prophylaxis with intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> or oral <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a> should be given.</p><p>If the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> is not administered pretransplant, we recommend against administration post-transplant in most patients due to concern for disseminated varicella-zoster virus (VZV) infection. An exception is varicella-nonimmune pediatric renal or liver transplant recipients who are receiving minimal or no immunosuppression and who have had no recent allograft rejection; the IDSA has endorsed varicella vaccination post-transplant in this group of patients [<a href="#rid6">6</a>]. When indicated, the varicella vaccine should be given as the single antigen preparation rather than as part of the combined measles, mumps, rubella, and varicella vaccine.</p><p>Preliminary data are encouraging regarding the efficacy of varicella immunization for stable patients after liver, kidney, and intestinal transplantation [<a href="#rid97">97-99</a>]. </p><p>As an example, in one study, 16 VZV-naïve pediatric renal and liver transplant recipients were immunized with the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> during the late post-transplant period (range eight months to six years) [<a href="#rid98">98</a>]. Evidence of humoral immunity developed in 13 of 15 patients (87 percent) and cell-mediated immunity developed in 12 of 14 patients (86 percent). Following vaccination, four patients had fever and four developed vesicular rashes, three of whom received <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>. Subsequent VZV exposures in four patients, one of whom received <a class="drug drug_general" data-topicid="9442" href="/d/drug information/9442.html" rel="external">varicella-zoster immune globulin</a>, did not result in VZV infection. Case reports of disseminated VZV have been described following varicella vaccination in solid organ transplant recipients [<a href="#rid100">100-102</a>]; some were proven to be caused by the vaccine strain [<a href="#rid100">100,102</a>].</p><p>Prior to widespread vaccination, varicella-zoster infection (chickenpox) occurred in up to 2 percent of pediatric renal transplant recipients in the first year after transplantation and was associated with significant morbidity and mortality [<a href="#rid103">103</a>]. Although adults are rarely susceptible to varicella, morbidity and mortality is high in those who acquire primary infection after transplantation. Although the recombinant shingles vaccine (Shingrix) is not licensed and has not been extensively studied for prevention of varicella in nonimmune subjects, early data demonstrate it can be a safe and effective option. In a small randomized study of 23 adult VZV-seronegative solid organ transplant recipients, 55 percent had a positive seroresponse four weeks after completing the vaccine series and no serious adverse effects were described [<a href="#rid104">104</a>]. </p><p class="headingAnchor" id="H22"><span class="h2">Rotavirus</span><span class="headingEndMark"> — </span>Rotavirus infection can lead to significant morbidity among solid organ transplant recipients and is particularly prevalent among pediatric solid organ transplant recipients [<a href="#rid105">105</a>]. Age-appropriate rotavirus vaccination is recommended for pediatric solid organ transplant candidates prior to transplantation but is not recommended following transplantation because it is a live vaccine [<a href="#rid8">8</a>]. Good infection control practices, including hand hygiene (especially after diaper changes), are recommended for immunocompromised household members of a recently vaccinated infant. (See  <a class="medical medical_review" href="/d/html/6023.html" rel="external">"Rotavirus vaccines for infants", section on 'Schedule'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">POSTEXPOSURE PROPHYLAXIS</span><span class="headingEndMark"> — </span>Postexposure prophylaxis (PEP) may be warranted for selected immunocompromised patients who have been exposed to certain pathogens, including varicella-zoster virus (VZV), influenza virus, hepatitis B virus, measles virus, meningococcus, rabies virus, and tetanus. Although the decision to use PEP is usually individualized based on the type of exposure, timing of the exposure, and degree of immunosuppression, it is often prudent to provide PEP for patients who have not been vaccinated against the pathogen to which they were exposed and/or for those who are severely immunocompromised.</p><p class="headingAnchor" id="H2126811125"><span class="h2">Varicella exposure</span><span class="headingEndMark"> — </span>For nonimmune solid organ transplant recipients who have been exposed to a patient with VZV (varicella or herpes zoster) infection, we recommend prophylaxis with VariZIG and/or antiviral therapy. Solid organ transplant recipients with immunity to VZV (VZV IgG positive) do not require VZV prophylaxis following exposure to a patient with VZV infection.</p><p>In the outpatient environment, significant exposure is defined as exposure to a household contact or nontransient face-to-face contact indoors with a playmate or other contact [<a href="#rid8">8,106</a>]. In the hospital environment, significant exposure is defined as exposure in the same two- to four-bed room, face-to-face contact with an infectious staff member or patient, or a visit by a person deemed contagious. All transplant recipients should be monitored carefully after exposure, even if VariZIG or antiviral therapy is administered.</p><p>VariZIG is a purified human varicella-zoster immunoglobulin preparation [<a href="#rid83">83,107</a>]. When postexposure prophylaxis is indicated, VariZIG should be offered as soon as possible, but it may be given for up to 10 days following exposure. Immunoprophylaxis alone does not prevent all cases of varicella in immunocompromised patients, but it lessens the severity of infection [<a href="#rid8">8</a>]. For high-risk patients who have additional exposures to varicella-zoster virus ≥3 weeks after initial VariZIG administration, another dose of VariZIG should be considered. (See  <a class="medical medical_review" href="/d/html/8273.html" rel="external">"Post-exposure prophylaxis against varicella-zoster virus infection"</a>.)</p><p>Use of antiviral agents (ie, <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a>, <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a>) as postexposure prophylaxis has not been evaluated in randomized trials in immunocompromised patients, but it should be considered as adjunctive therapy in patients receiving immunoprophylaxis or in patients who were unable to receive immunoprophylaxis within 10 days following exposure. Although either oral acyclovir or valacyclovir can be used for postexposure prophylaxis, we prefer valacyclovir (1 g orally three times daily) given its superior bioavailability. The optimal prophylactic regimen is not known, and approaches vary among experts [<a href="#rid83">83,106</a>]. We typically give antiviral prophylaxis from days 3 to 28 after known exposure for patients who have been given immunoprophylaxis. The antiviral is started on day 3 following exposure because of the theoretical concern that VariZIG might prolong VZV's incubation period [<a href="#rid108">108,109</a>]. For patients who have not received immunoprophylaxis, we treat for 22 days following exposure.</p><p>All patients who have been exposed should also be monitored closely for any sign of active infection; intravenous <a class="drug drug_general" data-topicid="9335" href="/d/drug information/9335.html" rel="external">acyclovir</a> should be started immediately should this occur [<a href="#rid110">110</a>].</p><p class="headingAnchor" id="H2940553703"><span class="h2">Other exposures</span><span class="headingEndMark"> — </span>Other PEP regimens vary based on the pathogen and may include antimicrobial prophylaxis, vaccination, and/or passive immunization (ie, generic or pathogen-specific <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>). For immunocompromised patients, live vaccines recommended in some PEP regimens may need to be replaced or supplemented with immunoglobulin administration.</p><p>Specific PEP indications and recommendations are discussed separately for each pathogen:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7017.html" rel="external">"Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults", section on 'Exposure to hepatitis B virus'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults", section on 'Post-exposure prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1274.html" rel="external">"Treatment and prevention of meningococcal infection", section on 'Antimicrobial chemoprophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8303.html" rel="external">"Rabies immune globulin and vaccine", section on 'Post-exposure prophylaxis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7661.html" rel="external">"Infectious complications of puncture wounds"</a>.)</p><p></p><p class="headingAnchor" id="H80302730"><span class="h1">HEALTH CARE WORKERS AND CLOSE CONTACTS</span><span class="headingEndMark"> — </span>Health care workers and close contacts (eg, family members) of solid organ transplant recipients should receive all recommended immunizations [<a href="#rid6">6,8</a>]. In particular, such individuals should be immunized against influenza annually, but they should also receive other indicated vaccines, including COVID-19. The following figures summarize routine vaccine recommendations for children  (<a class="graphic graphic_figure graphicRef82617" href="/d/graphic/82617.html" rel="external">figure 1B</a> and <a class="graphic graphic_figure graphicRef58209" href="/d/graphic/58209.html" rel="external">figure 1A</a>), healthy adults  (<a class="graphic graphic_figure graphicRef82634" href="/d/graphic/82634.html" rel="external">figure 2</a>), and adults with medical conditions  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1C</a>). (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines"</a> and  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/3889.html" rel="external">"Immunizations for health care providers"</a> and  <a class="medical medical_review" href="/d/html/2876.html" rel="external">"Standard immunizations for children and adolescents: Overview", section on 'Routine schedule'</a> and  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.) </p><p>With the exception of the <a class="drug drug_general" data-topicid="10175" href="/d/drug information/10175.html" rel="external">smallpox vaccine</a> and oral polio virus vaccines, there is little to no risk of transmission of vaccine viruses from vaccine recipients to their close contacts [<a href="#rid8">8</a>]. Nevertheless, health care workers and close contacts of solid organ transplant recipients should receive inactivated vaccines, especially COVID-19, when possible.</p><p>Specific issues in regard to certain live vaccines are discussed below. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza</strong> – The American Society of Transplantation (AST) favors the use of the <a class="drug drug_general" data-topicid="9055" href="/d/drug information/9055.html" rel="external">inactivated influenza vaccine</a> (IIV) for contacts of solid organ transplant recipients; they state that if the <a class="drug drug_general" data-topicid="9056" href="/d/drug information/9056.html" rel="external">live attenuated influenza vaccine</a> (LAIV) is the only available option, it can be given, but vaccine recipients should wash their hands frequently for two weeks following vaccination [<a href="#rid8">8</a>]. We agree with this approach. In contrast, the Infectious Diseases Society of America (IDSA) recommend either IIV or LAIV for contacts of solid organ transplant recipients; LAIV can be used in healthy nonpregnant individuals between 2 and 49 years of age [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/5960.html" rel="external">"Seasonal influenza in children: Prevention with vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MMR</strong> – Nonimmune household and close contacts of solid organ transplant recipients should be immunized against measles, mumps, and rubella (MMR) to prevent transmission of wild-type viruses to transplant recipients [<a href="#rid6">6,8,42</a>]. (See  <a class="medical medical_review" href="/d/html/3893.html" rel="external">"Measles, mumps, and rubella immunization in adults"</a> and  <a class="medical medical_review" href="/d/html/101273.html" rel="external">"Measles, mumps, and rubella immunization in infants, children, and adolescents", section on 'Measles, mumps, and rubella disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Varicella</strong> – The use of the <a class="drug drug_general" data-topicid="10038" href="/d/drug information/10038.html" rel="external">varicella vaccine</a> in household contacts of transplant recipients has been the subject of much discussion. The American Academy of Pediatrics (AAP) recommends use of the varicella vaccine in household contacts but cautions that vaccinees who develop a rash should avoid contact with transplant recipients for the duration of the rash [<a href="#rid106">106</a>]. The AST and IDSA guidelines also support this view and recommend that close contacts and family members aged 12 months or older should be vaccinated against varicella if they have never received the vaccination, have no history of varicella or herpes zoster, and have no contraindications to vaccination [<a href="#rid6">6,8</a>]. Transplant recipients should be isolated from vaccine recipients who develop a rash. If isolation is not possible, then the nonvaricella-immune transplant recipient should be monitored for the development of a rash, and antiviral therapy (eg, <a class="drug drug_general" data-topicid="10034" href="/d/drug information/10034.html" rel="external">valacyclovir</a> or <a class="drug drug_general" data-topicid="8435" href="/d/drug information/8435.html" rel="external">famciclovir</a>) should be started in the unlikely event that a rash suggestive of varicella develops. (See  <a class="medical medical_review" href="/d/html/8275.html" rel="external">"Vaccination for the prevention of chickenpox (primary varicella infection)", section on 'Contacts of immunocompromised hosts'</a>.)</p><p></p><p class="bulletIndent1">Similarly, the zoster vaccine should be administered to household contacts who have an indication to receive it. We generally prefer to use the <a class="drug drug_general" data-topicid="115351" href="/d/drug information/115351.html" rel="external">recombinant zoster vaccine</a> (RZV) for household contacts of solid organ transplant recipients rather than the live zoster virus vaccine because there is not risk of transmission of vaccine stain virus with RZV.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rotavirus</strong> – <a class="drug drug_general" data-topicid="10273" href="/d/drug information/10273.html" rel="external">Rotavirus vaccines</a> are given routinely to healthy infants and pose a theoretical risk of transmission since live virus may be shed in stool for two to four weeks following vaccination [<a href="#rid6">6,111-113</a>]. Highly immunocompromised patients (eg, solid organ transplant recipients within the first two months following transplantation) should avoid handling the diapers of infants who have received the rotavirus vaccine for four weeks following vaccination [<a href="#rid6">6</a>]. In addition, good handwashing practices should be adhered to among those who change the diapers of infants who received the rotavirus vaccine [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/d/html/6023.html" rel="external">"Rotavirus vaccines for infants"</a>.)</p><p></p><p>Pets should also receive routine vaccines, including the live intranasal canine <em>Bordetella bronchiseptica </em>vaccine [<a href="#rid8">8</a>]. Transplant recipients should not be in the same room when this is administered, to avoid potential illness from this live attenuated vaccine [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H317494028"><span class="h1">LIVING DONORS</span><span class="headingEndMark"> — </span>Living donors should be vaccinated according to recommendations for healthy individuals issued by the United States Advisory Committee on Immunization Practices (or, for those outside the United States, other national guidelines) [<a href="#rid6">6</a>]. Influenza vaccination is particularly important when transplantation occurs during influenza season. (See  <a class="medical medical_review" href="/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a>.)</p><p>Live virus vaccines should be avoided within four weeks of organ donation  (<a class="graphic graphic_table graphicRef112956" href="/d/graphic/112956.html" rel="external">table 6</a>) [<a href="#rid6">6</a>]. Vaccination of donors for the potential benefit of the recipient is not recommended.</p><p class="headingAnchor" id="H26"><span class="h1">IMMUNIZATIONS IN TRAVELERS</span><span class="headingEndMark"> — </span>Immunizations in travelers are discussed separately. The use of the different vaccines must be considered in relation to the issues described above. (See  <a class="medical medical_review" href="/d/html/3896.html" rel="external">"Travel advice for immunocompromised hosts", section on 'Routine vaccines'</a> and  <a class="medical medical_review" href="/d/html/3896.html" rel="external">"Travel advice for immunocompromised hosts", section on 'Travel vaccines'</a>.)</p><p class="headingAnchor" id="H3586702101"><span class="h1">GUIDELINES</span><span class="headingEndMark"> — </span>In 2019, the American Society of Transplantation (AST) updated the guidelines for vaccination of pediatric and adult solid organ transplant candidates and recipients as well as health care workers, household contacts, and other close contacts of these patients [<a href="#rid8">8</a>]. In 2013, the Infectious Diseases Society of America (IDSA) published guidelines for vaccination of immunocompromised hosts, including solid organ transplant recipients [<a href="#rid6">6</a>]. The United States Advisory Committee on Immunization Practices (ACIP) also includes immunocompromised hosts in their recommendations  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 1C</a>) [<a href="#rid115">115</a>].</p><p>Our recommendations are generally in keeping with the AST guidelines, the IDSA guidelines, and the ACIP recommendations. Clinicians in other countries should consider referring to their national guidelines for recommendations regarding immunization of solid organ transplant candidates and recipients. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H4028264871"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111313.html" rel="external">"Society guideline links: Immunizations in solid organ transplant recipients"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> − Vaccine-preventable infections cause substantial morbidity and mortality in solid organ transplant recipients. Thus, vaccination is an important part of care. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretransplant evaluation</strong> − Prior to transplantation, we review each patient's vaccination and exposure history in detail and administer any needed vaccinations  (<a class="graphic graphic_table graphicRef122440" href="/d/graphic/122440.html" rel="external">table 1</a>). (See <a class="local">'Pretransplant'</a> above and  <a class="medical medical_review" href="/d/html/1398.html" rel="external">"Evaluation for infection before solid organ transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of immunizations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaccines should be administered as early in the pretransplant period as possible when the likelihood of developing a protective immune response is highest and when live vaccines can be given safely. Live vaccines should be given at least four weeks prior to transplantation in immunocompetent patients. With rare exception, live vaccines are contraindicated in immunocompromised patients and post-transplantation. (See <a class="local">'Timing of immunizations'</a> above and <a class="local">'Live virus vaccines'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Post-transplantation, inactivated vaccines are considered safe, although their efficacy may be diminished. To maximize immune response, we generally wait at least 3 months and often up to 12 months post-transplant to give any needed inactivated (nonlive) vaccines. However, during influenza outbreaks, the inactivated influenza virus can be given as early as one month post-transplantation. (See <a class="local">'Post-transplant'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Influenza vaccines </strong>− Vaccination against seasonal influenza virus should be given annually both pre- and post-transplantation. Post-transplantation, we suggest using the high-dose influenza vaccine for adults because it augments immune response and does not appear to increase the likelihood of rejection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). However, using the standard-dose vaccine is also reasonable. (See <a class="local">'Influenza'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumococcal vaccines</strong> − We vaccinate solid organ transplant candidates and recipients against pneumococcus with either the <a class="drug drug_general" data-topicid="131831" href="/d/drug information/131831.html" rel="external">20-valent pneumococcal conjugate vaccine</a> (PCV20) alone or the <a class="drug drug_general" data-topicid="132100" href="/d/drug information/132100.html" rel="external">15-valent pneumococcal conjugate vaccine</a> (PCV15) followed by the 23-valent polysaccharide pneumococcal vaccine (<a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">PPSV23</a>) at least eight weeks later. For patients who have already received either the PPSV23 or an older formulation of the pneumococcal conjugate vaccine (eg, <a class="drug drug_general" data-topicid="9906" href="/d/drug information/9906.html" rel="external">13-valent pneumococcal conjugate vaccine</a> [PCV13], <a class="drug drug_general" data-topicid="17136" href="/d/drug information/17136.html" rel="external">10-valent pneumococcal conjugate vaccine</a> [PCV10]) previously, the dosing schedule varies  (<a class="graphic graphic_table graphicRef143140" href="/d/graphic/143140.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef143139" href="/d/graphic/143139.html" rel="external">table 3</a>). (See <a class="local">'Pneumococcus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hepatitis A and B vaccines</strong> − The hepatitis B virus vaccine series should be given to solid organ transplant candidates and recipients who are nonimmune to the virus based on serologic testing. Like the hepatitis A virus (HAV) vaccines, vaccination is particularly important for liver transplant candidates and recipients who are at increased risk of fulminant hepatic failure from these viruses. The HAV vaccine is also indicated for most pediatric solid organ transplant recipients and all nonliver solid organ transplant recipients with specific risk factors (eg, travel to or residence in a HAV-endemic area). (See <a class="local">'Hepatitis B'</a> above and <a class="local">'Hepatitis A'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes zoster vaccines</strong> − Vaccination against herpes zoster (shingles) is indicated for solid organ transplant candidates and recipients who are ≥19 years old. Vaccination should ideally be given pretransplantation to allow for maximal immunogenic response. For solid organ transplant recipients who are post-transplantation who have not received a herpes zoster vaccine, RZV should be administered; ZVL is <strong>contraindicated</strong> post-transplantation. (See <a class="local">'Zoster vaccines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19 vaccines</strong> − COVID-19 vaccination in SOT candidates and recipients is discussed separately. (See  <a class="medical medical_review" href="/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a> and  <a class="medical medical_review" href="/d/html/127582.html" rel="external">"COVID-19: Issues related to solid organ transplantation", section on 'Vaccination'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other vaccines</strong> − Additional vaccines may be needed for patients based on age, vaccination history, or other specific risk factors (eg, meningococcal vaccination for patients receiving <a class="drug drug_general" data-topicid="8836" href="/d/drug information/8836.html" rel="external">eculizumab</a>). (See <a class="local">'Human papillomavirus'</a> above and <a class="local">'Haemophilus influenzae'</a> above and <a class="local">'Tetanus, diphtheria, and pertussis'</a> above and <a class="local">'Live virus vaccines'</a> above and <a class="local">'Meningococcus'</a> above and <a class="local">'Respiratory syncytial virus (RSV)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postexposure prophylaxis</strong> − Following exposure to certain pathogens (eg, varicella-zoster virus, measles virus, or hepatitis B virus), passive immunization (eg, administration of immunoglobulin) and/or postexposure antimicrobial prophylaxis may be warranted for severely immunocompromised patients and/or for those who have not been vaccinated against these pathogens. (See <a class="local">'Postexposure prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Health care workers and close contacts</strong> − We advise that close contacts of solid organ transplant candidates receive all recommended immunizations. When possible, live virus vaccines should be given prior to transplantation and/or the start of immunosuppression. (See <a class="local">'Health care workers and close contacts'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Chong PP, Avery RK. A Comprehensive Review of Immunization Practices in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients. Clin Ther 2017; 39:1581.</a></li><li><a class="nounderline abstract_t">Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One 2013; 8:e56974.</a></li><li><a class="nounderline abstract_t">Gangappa S, Kokko KE, Carlson LM, et al. Immune responsiveness and protective immunity after transplantation. Transpl Int 2008; 21:293.</a></li><li><a class="nounderline abstract_t">Croce E, Hatz C, Jonker EF, et al. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Vaccine 2017; 35:1216.</a></li><li><a class="nounderline abstract_t">Al Jurdi A, Gassen RB, Borges TJ, et al. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination. Front Immunol 2022; 13:838985.</a></li><li><a class="nounderline abstract_t">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</a></li><li><a class="nounderline abstract_t">Blanchard-Rohner G, Enriquez N, Lemaître B, et al. Usefulness of a systematic approach at listing for vaccine prevention in solid organ transplant candidates. Am J Transplant 2019; 19:512.</a></li><li><a class="nounderline abstract_t">Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant 2019; 33:e13563.</a></li><li class="breakAll">Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season. Morbidity and Mortality Weekly Report (MMWR), Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/volumes/72/rr/rr7202a1.htm (Accessed on October 05, 2023).</li><li><a class="nounderline abstract_t">Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999; 67:753.</a></li><li><a class="nounderline abstract_t">Kimball P, Verbeke S, Flattery M, et al. Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients. Transplantation 2000; 69:2449.</a></li><li><a class="nounderline abstract_t">Lawal A, Basler C, Branch A, et al. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004; 4:1805.</a></li><li><a class="nounderline abstract_t">Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. J Heart Lung Transplant 2005; 24:588.</a></li><li><a class="nounderline abstract_t">White-Williams C, Brown R, Kirklin J, et al. Improving clinical practice: should we give influenza vaccinations to heart transplant patients? J Heart Lung Transplant 2006; 25:320.</a></li><li><a class="nounderline abstract_t">Scharpé J, Evenepoel P, Maes B, et al. Influenza vaccination is efficacious and safe in renal transplant recipients. Am J Transplant 2008; 8:332.</a></li><li><a class="nounderline abstract_t">Hurst FP, Lee JJ, Jindal RM, et al. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 2011; 6:1192.</a></li><li><a class="nounderline abstract_t">Natori Y, Shiotsuka M, Slomovic J, et al. A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients. Clin Infect Dis 2018; 66:1698.</a></li><li><a class="nounderline abstract_t">Mombelli M, Rettby N, Perreau M, et al. Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial. Vaccine 2018; 36:6163.</a></li><li><a class="nounderline abstract_t">Mombelli M, Neofytos D, Huynh-Do U, et al. Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial. Clin Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15:355.</a></li><li><a class="nounderline abstract_t">Vilchez RA, McCurry K, Dauber J, et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2:287.</a></li><li><a class="nounderline abstract_t">Sanchez-Fructuoso AI, Prats D, Naranjo P, et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000; 69:436.</a></li><li><a class="nounderline abstract_t">Fraund S, Wagner D, Pethig K, et al. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant 1999; 18:220.</a></li><li><a class="nounderline abstract_t">Madan RP, Tan M, Fernandez-Sesma A, et al. A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings. Clin Infect Dis 2008; 46:712.</a></li><li><a class="nounderline abstract_t">Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22:295.</a></li><li><a class="nounderline abstract_t">Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000; 61:85.</a></li><li><a class="nounderline abstract_t">Kumar D, Ferreira VH, Blumberg E, et al. A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients. Clin Infect Dis 2018; 67:1322.</a></li><li><a class="nounderline abstract_t">Harboe ZB, Modin D, Gustafsson F, et al. Effect of influenza vaccination in solid organ transplant recipients: A nationwide population-based cohort study. Am J Transplant 2022; 22:2409.</a></li><li><a class="nounderline abstract_t">Schuurmans MM, Tini GM, Dalar L, et al. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant 2011; 30:685.</a></li><li><a class="nounderline abstract_t">Egli A, Humar A, Widmer LA, et al. Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. J Infect Dis 2015; 212:137.</a></li><li><a class="nounderline abstract_t">Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009; 9:493.</a></li><li><a class="nounderline abstract_t">Chong PP, Handler L, Weber DJ. A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients. Clin Infect Dis 2018; 66:1802.</a></li><li><a class="nounderline abstract_t">Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial. Clin Infect Dis 2017; 64:829.</a></li><li><a class="nounderline abstract_t">Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant 2008; 8:9.</a></li><li><a class="nounderline abstract_t">Blumberg EA, Fitzpatrick J, Stutman PC, et al. Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 1998; 17:1075.</a></li><li><a class="nounderline abstract_t">Candon S, Thervet E, Lebon P, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009; 9:2346.</a></li><li><a class="nounderline abstract_t">Mulley WR, Dendle C, Ling JEH, Knight SR. Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis. J Heart Lung Transplant 2018; 37:844.</a></li><li><a class="nounderline abstract_t">Dos Santos G, Haguinet F, Cohet C, et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series. Vaccine 2016; 34:3598.</a></li><li><a class="nounderline abstract_t">Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:109.</a></li><li><a class="nounderline abstract_t">Nuorti JP, Whitney CG, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013; 62:521.</a></li><li class="breakAll">American Academy of Pediatrics. Immunization in immunocompromised children. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL  p.74.</li><li><a class="nounderline abstract_t">Dengler TJ, Strnad N, Bühring I, et al. Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation. Transplantation 1998; 66:1340.</a></li><li><a class="nounderline abstract_t">Kumar D, Rotstein C, Miyata G, et al. Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients. J Infect Dis 2003; 187:1639.</a></li><li><a class="nounderline abstract_t">Kumar D, Welsh B, Siegal D, et al. Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant 2007; 7:633.</a></li><li><a class="nounderline abstract_t">Kumar D, Chen MH, Wong G, et al. A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients. Clin Infect Dis 2008; 47:885.</a></li><li><a class="nounderline abstract_t">Dendle C, Stuart RL, Mulley WR, Holdsworth SR. Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence. Vaccine 2018; 36:6253.</a></li><li><a class="nounderline abstract_t">Klein NP, Peyrani P, Yacisin K, et al. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine 2021; 39:5428.</a></li><li><a class="nounderline abstract_t">Song JY, Chang CJ, Andrews C, et al. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH). Vaccine 2021; 39:6422.</a></li><li><a class="nounderline abstract_t">Idilman R, De MN, Colantoni A, et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C. Am J Gastroenterol 2002; 97:435.</a></li><li><a class="nounderline abstract_t">Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 Suppl B:59B.</a></li><li><a class="nounderline abstract_t">Domínguez M, Bárcena R, García M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000; 6:440.</a></li><li><a class="nounderline abstract_t">Kallinowski B, Benz C, Buchholz L, Stremmel W. Accelerated schedule of hepatitis B vaccination in liver transplant candidates. Transplant Proc 1998; 30:797.</a></li><li><a class="nounderline abstract_t">Chung RT, Feng S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001; 1:185.</a></li><li><a class="nounderline abstract_t">Loinaz C, de Juanes JR, Gonzalez EM, et al. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997; 44:235.</a></li><li><a class="nounderline abstract_t">Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37:1329.</a></li><li><a class="nounderline abstract_t">Serrano B, Bayas JM, Bruni L, Díez C. Solid organ transplantation and response to vaccination. Vaccine 2007; 25:7331.</a></li><li><a class="nounderline abstract_t">Grob PJ, Binswanger U, Zaruba K, et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 1983; 3:43.</a></li><li><a class="nounderline abstract_t">Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94:1601.</a></li><li><a class="nounderline abstract_t">Garcia Garrido HM, Wieten RW, Grobusch MP, Goorhuis A. Response to Hepatitis A Vaccination in Immunocompromised Travelers. J Infect Dis 2015; 212:378.</a></li><li><a class="nounderline abstract_t">Stark K, Günther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 1999; 180:2014.</a></li><li><a class="nounderline abstract_t">Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72:272.</a></li><li><a class="nounderline abstract_t">Jeon HJ, Ro H, Jeong JC, et al. Efficacy and safety of hepatitis A vaccination in kidney transplant recipients. Transpl Infect Dis 2014; 16:511.</a></li><li><a class="nounderline abstract_t">Arslan M, Wiesner RH, Poterucha JJ, et al. Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation. Liver Transpl 2000; 6:191.</a></li><li><a class="nounderline abstract_t">Günther M, Stark K, Neuhaus R, et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71:477.</a></li><li><a class="nounderline abstract_t">Bakker M, Bunge EM, Marano C, et al. Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review. Expert Rev Vaccines 2016; 15:829.</a></li><li><a class="nounderline abstract_t">Human papillomavirus infection. Am J Transplant 2004; 4 Suppl 10:95.</a></li><li><a class="nounderline abstract_t">Chin-Hong PV, Reid GE, AST Infectious Diseases Community of Practice. Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13590.</a></li><li><a class="nounderline abstract_t">Kumar D, Unger ER, Panicker G, et al. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant 2013; 13:2411.</a></li><li><a class="nounderline abstract_t">Boey L, Curinckx A, Roelants M, et al. Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV). Clin Infect Dis 2021; 73:e661.</a></li><li><a class="nounderline abstract_t">Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Enke BU, Bökenkamp A, Offner G, et al. Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients. Transplantation 1997; 64:237.</a></li><li><a class="nounderline abstract_t">Huzly D, Neifer S, Reinke P, et al. Routine immunizations in adult renal transplant recipients. Transplantation 1997; 63:839.</a></li><li><a class="nounderline abstract_t">Girndt M, Pietsch M, Köhler H. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. Am J Kidney Dis 1995; 26:454.</a></li><li><a class="nounderline abstract_t">Krüger S, Müller-Steinhardt M, Kirchner H, Kreft B. A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients. Am J Kidney Dis 2001; 38:1264.</a></li><li><a class="nounderline abstract_t">Murthy N, Wodi AP, McNally VV, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2024. MMWR Morb Mortal Wkly Rep 2024; 73:11.</a></li><li><a class="nounderline abstract_t">Dooling KL, Guo A, Patel M, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep 2018; 67:103.</a></li><li><a class="nounderline abstract_t">Anderson TC, Masters NB, Guo A, et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:80.</a></li><li><a class="nounderline abstract_t">Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial. Clin Infect Dis 2020; 70:181.</a></li><li><a class="nounderline abstract_t">Hirzel C, L'Huillier AG, Ferreira VH, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant 2021; 21:2246.</a></li><li><a class="nounderline abstract_t">McGirr A, Widenmaier R, Curran D, et al. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. Vaccine 2019; 37:2896.</a></li><li><a class="nounderline abstract_t">Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4:138.</a></li><li><a class="nounderline abstract_t">Anibarro L, Trigo M, Feijoó D, et al. Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis. BMC Infect Dis 2012; 12:195.</a></li><li><a class="nounderline abstract_t">Rogerson TE, Chen S, Kok J, et al. Tests for latent tuberculosis in people with ESRD: a systematic review. Am J Kidney Dis 2013; 61:33.</a></li><li><a class="nounderline abstract_t">Schulman SL, Deforest A, Kaiser BA, et al. Response to measles-mumps-rubella vaccine in children on dialysis. Pediatr Nephrol 1992; 6:187.</a></li><li><a class="nounderline abstract_t">Flynn JT, Frisch K, Kershaw DB, et al. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15:269.</a></li><li><a class="nounderline abstract_t">Palumbo P, Hoyt L, Demasio K, et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11:1008.</a></li><li class="breakAll">Ellis D, Gilboa N, Bellinger M, Shapiro R. Renal transplantation in infants and children. In: Renal Transplantation, Shaprio R, Simmons RL, Starzl TE (Eds), Appleton and Lange, Stamford, CT 1997. p.461.</li><li><a class="nounderline abstract_t">Pittet LF, Verolet CM, McLin VA, et al. Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation. Am J Transplant 2019; 19:844.</a></li><li><a class="nounderline abstract_t">Verolet CM, Posfay-Barbe KM. Live virus vaccines in transplantation: friend or foe? Curr Infect Dis Rep 2015; 17:472.</a></li><li><a class="nounderline abstract_t">Rand EB, McCarthy CA, Whitington PF. Measles vaccination after orthotopic liver transplantation. J Pediatr 1993; 123:87.</a></li><li><a class="nounderline abstract_t">Broyer M, Tete MJ, Guest G, et al. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99:35.</a></li><li><a class="nounderline abstract_t">Webb NJ, Fitzpatrick MM, Hughes DA, et al. Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group. Arch Dis Child 2000; 82:141.</a></li><li><a class="nounderline abstract_t">Furth SL, Hogg RJ, Tarver J, et al. Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol 2003; 18:33.</a></li><li><a class="nounderline abstract_t">Barton M, Wasfy S, Melbourne T, et al. Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy. Pediatr Transplant 2009; 13:1007.</a></li><li><a class="nounderline abstract_t">Zamora I, Simon JM, Da Silva ME, Piqueras AI. Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 1994; 8:190.</a></li><li><a class="nounderline abstract_t">Weinberg A, Horslen SP, Kaufman SS, et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006; 6:565.</a></li><li><a class="nounderline abstract_t">Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006; 10:78.</a></li><li><a class="nounderline abstract_t">Kraft JN, Shaw JC. Varicella infection caused by Oka strain vaccine in a heart transplant recipient. Arch Dermatol 2006; 142:943.</a></li><li><a class="nounderline abstract_t">Levitsky J, Te HS, Faust TW, Cohen SM. Varicella infection following varicella vaccination in a liver transplant recipient. Am J Transplant 2002; 2:880.</a></li><li><a class="nounderline abstract_t">Berman MA, Rupp RE. Disseminated vaccine-induced varicella infection in a kidney transplant recipient. Am J Transplant 2023; 23:1806.</a></li><li><a class="nounderline abstract_t">Furth SL, Sullivan EK, Neu AM, et al. Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1997; 1:37.</a></li><li><a class="nounderline abstract_t">L'Huillier AG, Hirzel C, Ferreira VH, et al. Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients. Transplantation 2021; 105:2316.</a></li><li><a class="nounderline abstract_t">Stelzmueller I, Wiesmayr S, Swenson BR, et al. Rotavirus enteritis in solid organ transplant recipients: an underestimated problem? Transpl Infect Dis 2007; 9:281.</a></li><li class="breakAll">American Academy of Pediatrics. Varicella-Zoster Infections. In: Red Book 2021; Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2021.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Updated recommendations for use of VariZIG--United States, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:574.</a></li><li><a class="nounderline abstract_t">Boeckh M. Prevention of VZV infection in immunosuppressed patients using antiviral agents. Herpes 2006; 13:60.</a></li><li><a class="nounderline abstract_t">Weinstock DM, Boeckh M, Boulad F, et al. Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues. Infect Control Hosp Epidemiol 2004; 25:603.</a></li><li><a class="nounderline abstract_t">Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics 1992; 90:216.</a></li><li><a class="nounderline abstract_t">Smith CK, McNeal MM, Meyer NR, et al. Rotavirus shedding in premature infants following first immunization. Vaccine 2011; 29:8141.</a></li><li><a class="nounderline abstract_t">Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008; 8:642.</a></li><li><a class="nounderline abstract_t">Payne DC, Edwards KM, Bowen MD, et al. Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis. Pediatrics 2010; 125:e438.</a></li><li><a class="nounderline abstract_t">Gisel JJ, Brumble LM, Johnson MM. Bordetella bronchiseptica pneumonia in a kidney-pancreas transplant patient after exposure to recently vaccinated dogs. Transpl Infect Dis 2010; 12:73.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Immunization Schedules: Resources for Health Care Providers. https://www.cdc.gov/vaccines/schedules/hcp/resources.html (Accessed on October 24, 2022).</li></ol></div><div id="topicVersionRevision">Topic 3892 Version 57.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28751095" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A Comprehensive Review of Immunization Practices in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23451126" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Serologic vaccination response after solid organ transplantation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18225995" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Immune responsiveness and protective immunity after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28162821" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35281011" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311479" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30144276" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Usefulness of a systematic approach at listing for vaccine prevention in solid organ transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002409" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31002409" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Vaccination of solid organ transplant candidates and recipients: Guidelines from the American society of transplantation infectious diseases community of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10096534" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Influenza vaccination in liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868658" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Influenza vaccination does not promote cellular or humoral activation among heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15476480" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15896757" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16507426" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Improving clinical practice: should we give influenza vaccinations to heart transplant patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18162092" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Influenza vaccination is efficacious and safe in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511837" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcomes associated with influenza vaccination in the first year after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253089" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30181045" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunogenicity and safety of double versus standard dose of the seasonal influenza vaccine in solid-organ transplant recipients: A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37584344" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients: The STOP-FLU trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12130931" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Viral infections in immunocompromised patients: what's new with respiratory viruses?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12096793" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Influenza virus infection in adult solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706057" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10328147" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Influenza vaccination in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230041" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A prospective, comparative study of the immune response to inactivated influenza vaccine in pediatric liver transplant recipients and their healthy siblings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8838186" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The immunogenicity of influenza virus vaccine in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10745238" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of influenza vaccination in adult liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29635437" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35384275" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effect of influenza vaccination in solid organ transplant recipients: A nationwide population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444211" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25589334" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19628174" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253095" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28362949" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Two Doses of Inactivated Influenza Vaccine Improve Immune Response in Solid Organ Transplant Recipients: Results of TRANSGRIPE 1-2, a Randomized Controlled Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093271" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Update on immunizations in solid organ transplant recipients: what clinicians need to know.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855446" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety of influenza vaccine in heart transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656126" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29609844" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Does vaccination in solid-organ transplant recipients result in adverse immunologic sequelae? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27216760" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35085226" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21150868" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803961" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23803961" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9846520" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Differential immune response to influenza and pneumococcal vaccination in immunosuppressed patients after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12721944" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Randomized, double-blind, controlled trial of pneumococcal vaccination in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17217436" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18715160" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A randomized, double-blind, placebo-controlled trial to evaluate the prime-boost strategy for pneumococcal vaccination in adult liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30217523" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34315611" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34489128" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged ≥50 years: A randomized phase III trial (PNEU-PATH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866284" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10938507" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10915165" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9595103" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Accelerated schedule of hepatitis B vaccination in liver transplant candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12099368" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9058151" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hepatitis B vaccination results in 140 liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12774011" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17889412" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Solid organ transplantation and response to vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6347059" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614811" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10364031" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Immunogenicity of hepatitis A vaccine in decompensated liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25649170" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Response to Hepatitis A Vaccination in Immunocompromised Travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10558960" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477352" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Safety and efficacy of hepatitis A vaccination in liver transplantation recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24750343" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy and safety of hepatitis A vaccination in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10719019" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hepatitis A antibodies in liver transplant recipients: evidence for loss of immunity posttransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11233913" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840060" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Immunogenicity, effectiveness and safety of combined hepatitis A and B vaccine: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15504222" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Human papillomavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31077438" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837399" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33373429" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33417592" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9256180" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Response to diphtheria and tetanus booster vaccination in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9089223" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Routine immunizations in adult renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7645553" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11728959" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38206880" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370152" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35051134" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30843046" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33565711" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982636" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465007" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Varicella zoster virus in solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22905901" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23068425" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Tests for latent tuberculosis in people with ESRD: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1571219" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Response to measles-mumps-rubella vaccine in children on dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10682116" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1461690" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Population-based study of measles and measles immunization in human immunodeficiency virus-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1461690" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Population-based study of measles and measles immunization in human immunodeficiency virus-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171797" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Multimodal safety assessment of measles-mumps-rubella vaccination after pediatric liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25870140" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Live virus vaccines in transplantation: friend or foe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8320632" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Measles vaccination after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989334" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Varicella and zoster in children after kidney transplantation: long-term results of vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648369" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Immunisation against varicella in end stage and pre-end stage renal failure. Trans-Pennine Paediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12488988" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207222" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Sustainability of humoral responses to varicella vaccine in pediatric transplant recipients following a pretransplantation immunization strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8018498" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Attenuated varicella virus vaccine in children with renal transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16468967" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16499592" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Live virus immunization after orthotopic liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847227" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Varicella infection caused by Oka strain vaccine in a heart transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12392296" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Varicella infection following varicella vaccination in a liver transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37286085" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Disseminated vaccine-induced varicella infection in a kidney transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084785" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Varicella in the first year after renal transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33528118" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17605739" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Rotavirus enteritis in solid organ transplant recipients: an underestimated problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17605739" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Rotavirus enteritis in solid organ transplant recipients: an underestimated problem?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23863705" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Updated recommendations for use of VariZIG--United States, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17147908" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Prevention of VZV infection in immunosuppressed patients using antiviral agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15301035" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Postexposure prophylaxis against varicella-zoster virus infection among recipients of hematopoietic stem cell transplant: unresolved issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1322522" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Varicella in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21856359" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Rotavirus shedding in premature infants following first immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18922486" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Rotavirus vaccines: viral shedding and risk of transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100758" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Sibling transmission of vaccine-derived rotavirus (RotaTeq) associated with rotavirus gastroenteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19874567" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Bordetella bronchiseptica pneumonia in a kidney-pancreas transplant patient after exposure to recently vaccinated dogs.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
